NOVITIUM PHARMA LLC (United States) holds 12 active US FDA Type II Drug Master Files and has DMF or CEP filings on record for 12 active ingredients. 6 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “NOVITIUM PHARMA LLC: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/novitium-pharma-llc

Overview

NOVITIUM PHARMA LLC is an active pharmaceutical ingredient (API) supplier with 12 active FDA Type II Drug Master Files, covering BETAINE ANHYDROUS; CARGLUMIC ACID; DAPSONE USP; DIAZOXIDE USP; DICHLORPHENAMIDE USP; FLUDROCORTISONE ACETATE USP.

Core services & business areas

API ManufacturingPharmaceutical Manufacturing

Active ingredients with DMF or CEP filings

Substances for which NOVITIUM PHARMA LLC holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

NOVITIUM PHARMA LLC holds 12 active (12 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • FLUDROCORTISONE ACETATE USPActive2020-06-09
  • BETAINE ANHYDROUSActive2020-03-12
  • METHYLTESTOSTERONE USPActive2019-12-17
  • DICHLORPHENAMIDE USPActive2019-12-10
  • LEVORPHANOL TARTRATE USPActive2018-12-31
  • CARGLUMIC ACIDActive2018-12-07
  • OXANDROLONE USPActive2017-10-28
  • THIOTHIXENE USPActive2017-07-21
  • PRAZOSIN HYDROCHLORIDE USPActive2017-06-16
  • DIAZOXIDE USPActive2017-01-27
  • NITISINONEActive2017-01-02
  • DAPSONE USPActive2013-12-13

FDA compliance signals

6 FDA enforcement records linked to this company.

  • recall — Class III2024-04-24

    Failed Impurities/Degradation Specifications

  • recall — Class III2024-03-27

    Cross Contamination with Other Products:(mycophenolate mofetil).

  • recall — Class II2019-11-20

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-11-20

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-11-20

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-11-20

    CGMP Deviations: Presence of NDMA impurity detected in product.

For suppliers

Is this NOVITIUM PHARMA LLC?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.